Avity Investment Management Inc. Has $31.72 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Avity Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,263 shares of the medical research company’s stock after buying an additional 6,537 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Avity Investment Management Inc.’s holdings, making the stock its 21st biggest position. Avity Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $31,718,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TMO. Lexington Hill Partners LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth $223,000. Valeo Financial Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 1.3% in the 2nd quarter. Valeo Financial Advisors LLC now owns 2,690 shares of the medical research company’s stock worth $1,348,000 after acquiring an additional 34 shares in the last quarter. Atwood & Palmer Inc. lifted its position in shares of Thermo Fisher Scientific by 0.8% during the second quarter. Atwood & Palmer Inc. now owns 54,746 shares of the medical research company’s stock valued at $27,448,000 after purchasing an additional 443 shares in the last quarter. Rockland Trust Co. boosted its holdings in Thermo Fisher Scientific by 4.1% during the second quarter. Rockland Trust Co. now owns 64,639 shares of the medical research company’s stock worth $32,407,000 after purchasing an additional 2,546 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. increased its stake in Thermo Fisher Scientific by 169.1% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 374 shares of the medical research company’s stock valued at $187,000 after buying an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on TMO. Piper Sandler increased their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. This represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock valued at $12,235,950 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $593.11 on Friday. The company has a 50-day moving average price of $517.63 and a two-hundred day moving average price of $510.61. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $219.30 billion, a PE ratio of 31.90, a P/E/G ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.